Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
GLP-1 agonists including semaglutides like Ozempic and Wegovy and tirzepatides like Mounjaro and Zepbound were originally intended to treat type 2 diabetes and obesity
Funding This study was supported by research funding from the National Natural Science Foundation of China (No.82104251)
.jpg)
Any intervention that addresses these fundamental challenges holds promise for improving outcomes
That broader metabolic action supports both weight loss and improved glucose metabolism , which can be especially helpful for people living with obesity and type 2 diabetes
US$ 27.44
US$ 28.88
US$ 28.53
